

RECEIVED  
CENTRAL FAX CENTER

NOV 21 2006

## REMARKS

Claims 1-10, 12-33 and 35-43 are pending. Claims 11 and 34 were amended and Claims 1 and 28 canceled by preliminary amendment. The Examiner has required restriction in the above-identified application. Specifically, election of one of the following groups is required:

Groups I - XX: Claims 1-10, 12, 14, 15, 19, 20 and 23-27, drawn to a method for cancer therapy, comprising administering the combination of a cytokine-expressing cellular vaccine and a specific additional cancer therapeutic agent or a specific combination of additional cancer therapeutic agents selected from those listed in claim, classified in class 424, subclass 93.21. (Methods)

Groups XXI - XXXX: Claims 28-33 and 35-43, drawn to a composition comprising a cytokine-expressing cellular vaccine and a specific additional cancer therapeutic agent or a specific combination of additional cancer therapeutic agents selected from those listed in claim 1, classified in class 424, subclass 93.21. (Products)

Responsive to the Restriction/Election of Species Requirement in the above-captioned application, dated October 24, 2006, Applicants elect, Groups I - XX (Claims 1-10, 12, 14, 15, 19, 20 and 23-27), and in particular an anti-OX40 antibody with traverse, for further prosecution at this time.

Applicants submit that the application supports method claims that are generically drawn to any additional cancer therapeutic agent and respectfully submit that a generic claim exemplified by Claim 1 is allowable.

BEST AVAILABLE COPY

RECEIVED  
CENTRAL FAX CENTER

NOV 21 2006

**CONCLUSION**

In light of the above, Applicants submit that this application is now in condition for allowance and therefore request favorable consideration. If any issues remain which the Examiner feels may be best resolved through a personal or telephonic interview, the Examiner is respectfully requested to contact Applicants' counsel, Linda R. Judge at (415) 836-2586.


No fees beyond are believed to be due in connection with this Amendment. However, the Director is authorized to charge any additional fees that may required, or credit any overpayment, to DLA Piper US LLP Deposit Account No. 07-1896 (Order No. 3802-090-27 CIP (306229-114)).

Respectfully submitted,

Date: November 21, 2006**DLA PIPER US LLP****Customer No. 29585**

Telephone: 415/836.2500

Facsimile: 415/836.2501

  
Linda R. Judge  
Reg. No. 42,702